Nordic Nanovector

325 articles with Nordic Nanovector

• Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

  4/2/2019

  Nordic Nanovector ASA notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported in an oral presentation at TAT11, the 11th International Symposium on Targeted-Alpha-Therapy.

• Nordic Nanovector to Present at DNB's SME Conference and Kempen Life Science Conference

  3/28/2019

  Nordic Nanovector ASA announces that members of its senior management team will participate and present at the following upcoming investor conferences during April

• Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options - March 18, 2019

  3/18/2019

  An individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 17,392 options through exercise of a corresponding number of free-standing warrants. 14,374 of the options are exercised at a strike price of NOK 30.00 per share, and 3,018 of the options are exercised at a strike price of NOK 14.24.

• Nordic Nanovector ASA - Share Capital Increase Registered - March 14, 2019

  3/14/2019

  Reference is made to the stock exchange notice on 6 March 2019 where Nordic Nanovector ASA announced the final result of the repair offering, in which 69,051 shares, each with a nominal value of NOK 0.20, at a subscription price of NOK 45.00 were allocated.

• Financial Calendar for Nordic Nanovector ASA

  3/12/2019

  Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

• Nordic Nanovector to Attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar

  3/11/2019

  Nordic Nanovector ASA announces that members of its senior management team will participate and present at the following upcoming investor conferences during March

• Nordic Nanovector ASA - Final Result of the Repair Offering

  3/6/2019

  Reference is made to the stock exchange notice on 20 February 2019 where Nordic Nanovector ASA (the "Company") announced the commencement of a repair offering of up to 777,777 shares with a par value of NOK 0.20 each (the "Offer Shares") at a subscription price of NOK 45.00 per Offer Share (the "Repair Offering").

• Nordic Nanovector ASA: Increase of Share Capital

  3/4/2019

  The former chairman of Nordic Nanovector ASA, Ludvik Sandnes, has resolved to exercise a total number of 27,121 RSUs that were issued to him in 2016 and 2017 after he had elected to receive all of his remuneration in RSUs.

• Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2018

  2/27/2019

  Nordic Nanovector ASA announces its results for the fourth quarter and full year 2018.

• Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast

  2/20/2019

  Nordic Nanovector ASA announces that it will report its fourth quarter and full year 2018 results on Wednesday, 27 February 2019.

• Nordic Nanovector ASA: Extraordinary General Meeting Held - February 18, 2019

  2/18/2019

  Nordic Nanovector ASA announces that an extraordinary general meeting in the company was held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo.

• Nordic Nanovector ASA - Allocation of PSUs - January 31, 2019

  1/31/2019

  The Board of Directors of Nordic Nanovector ASA has on 31 January 2019 decided to grant 259,000 Performance Share Units to employees in accordance with the authorisation granted at the Annual General Meeting held on 30 May 2018.

• Nordic Nanovector ASA - Registration of Share Capital Increase in the Norwegian Register of Business Enterprises

  1/30/2019

  Reference is made to the stock exchange announcement regarding the successful completion of the private placement of Nordic Nanovector ASA published on 25 January 2019.

• Nordic Nanovector ASA - Notice of Extraordinary General Meeting

  1/28/2019

  The Board of Directors of Nordic Nanovector ASA call for an extraordinary general meeting to be held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo on 18 February 2019 at 15:00 CET.

• Nordic Nanovector ASA - Key Information Regarding Intentional Repair Offering

  1/25/2019

  Reference is made to the announcement by Nordic Nanovector ASA on 25 January 2019 concerning a private placement with gross proceeds in the amount of approximately NOK 222 million and a contemplated repair issue of up to 777,777 new shares with non-tradeable subscription rights to eligible shareholders.

• Nordic Nanovector Appoints Mark Wright as Head of Manufacturing

  1/2/2019

  Nordic Nanovector ASA announces the appointment of Dr Mark Wright as Head of Manufacturing.

• Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ASH

  12/4/2018

  Nordic Nanovector ASA notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies were made at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA).

• Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

  12/3/2018

  Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL)

• Nordic Nanovector ASA November 16, 2018: Increased Share Capital Following Exercise of Employee Share Options

  11/16/2018

  A individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share.

• Nordic Nanovector ASA: Results for the Third Quarter 2018

  11/6/2018

  Nordic Nanovector ASA (OSE: NANO) announces its third quarter 2018 results today.